Abstract
Mucopolysaccharidosis I-Hurler (MPS I-H) is caused by the loss of α-L-iduronidase, a lysosomal enzyme that degrades glycosaminoglycans. Current therapies cannot treat many MPS I-H manifestations. In this study, triamterene, an FDA-approved, antihypertensive diuretic, was found to suppress translation termination at a nonsense mutation associated with MPS I-H. Triamterene rescued enough α-L-iduronidase function to normalize glycosaminoglycan storage in cell and animal models. This new function of triamterene operates through premature termination codon (PTC) dependent mechanisms that are unaffected by epithelial sodium channel activity, the target of triamterene’s diuretic function. Triamterene represents a potential non-invasive treatment for MPS I-H patients carrying a PTC.
Funding Information
  • Scientific and Technological Research Council of Turkey (TUBITAK-2219, 1059B1916000563, P30DK072482, R21OD019922, ROWE19R0, BEDWEL19G0, KKEELIN15XX0)
  • National Institutes of Health (TUBITAK-2219, 1059B1916000563, P30DK072482, R21OD019922, ROWE19R0, BEDWEL19G0, KKEELIN15XX0)
  • Cystic Fibrosis Foundation (TUBITAK-2219, 1059B1916000563, P30DK072482, R21OD019922, ROWE19R0, BEDWEL19G0, KKEELIN15XX0)
  • Alabama Drug Discovery Alliance (TUBITAK-2219, 1059B1916000563, P30DK072482, R21OD019922, ROWE19R0, BEDWEL19G0, KKEELIN15XX0)
  • University of Pennsylvania Orphan Disease Center (TUBITAK-2219, 1059B1916000563, P30DK072482, R21OD019922, ROWE19R0, BEDWEL19G0, KKEELIN15XX0)

This publication has 44 references indexed in Scilit: